$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000114420419025261 Filed on May 10, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q4
Revenue	$9.250M	$6.477M	$8.991M
YoY Change	35.73%	9.72%	19.2%
Cost Of Revenue	$2.386M	$1.884M	$1.580M
YoY Change	43.05%	27.99%	-12.71%
Gross Profit	$6.864M	$4.593M	$7.410M
YoY Change	33.36%	3.66%	-105.84%
Gross Profit Margin	74.21%	70.91%	82.42%
Selling, General & Admin	$13.44M	$13.48M	$14.58M
YoY Change	2.96%	-17.36%	1.18%
% of Gross Profit	195.85%	293.49%	196.76%
Research & Development	$18.51M	$23.27M	$25.05M
YoY Change	1851000.0%	-6.75%	73.84%
% of Gross Profit	269.68%	506.71%	338.06%
Depreciation & Amortization	$500.0K	$481.0K	$740.0K
YoY Change	13.64%	145.41%	-161.67%
% of Gross Profit	7.28%	10.47%	9.99%
Operating Expenses	$31.95M	$39.09M	$39.63M
YoY Change	-63.87%	-2.47%	-135.89%
Operating Profit	-$25.29M	-$32.61M	-$41.21M
YoY Change	-21.49%	-4.58%	34.59%
Interest Expense	$2.207M	$1.847M	-$3.220M
YoY Change	2.94%	-11.33%	-55.03%
% of Operating Profit
Other Income/Expense, Net	-$2.190M	$16.35M
YoY Change	-77.38%	-930.1%
Pretax Income	-$27.48M	-$16.26M	-$34.63M
YoY Change	-19.83%	-55.02%	46.12%
Income Tax
% Of Pretax Income
Net Earnings	-$13.10M	$1.392M	-$24.88M
YoY Change	-39.39%	-106.62%	138.93%
Net Earnings / Revenue	-141.6%	21.49%	-276.72%
Basic Earnings Per Share		$0.03
Diluted Earnings Per Share	-$243.8K	$0.02	-$564.3K
COMMON SHARES
Basic Shares Outstanding	65.23M	48.51M	56.68M shares
Diluted Shares Outstanding		63.81M

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.4M	$121.5M	$83.10M
YoY Change	12.37%	-26.5%	-36.56%
Cash & Equivalents	$165.5M	$116.4M	$65.51M
Short-Term Investments	$5.000M	$5.000M	$17.60M
Other Short-Term Assets	$3.400M	$4.300M	$19.80M
YoY Change	-76.87%	-71.9%	-54.59%
Inventory	$700.0K	$629.0K	$678.0K
Prepaid Expenses
Receivables	$3.100M	$8.022M	$5.498M
Other Receivables	$1.900M	$2.200M	$2.100M
Total Short-Term Assets	$163.5M	$136.5M	$111.2M
YoY Change	-4.66%	-31.78%	-39.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.30M	$11.83M	$12.02M
YoY Change	1254.66%	458.42%	68.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.20M	$11.10M	$0.00
YoY Change	1766.67%	753.85%	-100.0%
Other Assets	$17.30M	$1.225M	$276.0K
YoY Change	-5.98%	30.88%	6.98%
Total Long-Term Assets	$63.80M	$63.99M	$29.79M
YoY Change	-2.45%	-1.43%	-52.55%
TOTAL ASSETS
Total Short-Term Assets	$163.5M	$136.5M	$111.2M
Total Long-Term Assets	$63.80M	$63.99M	$29.79M
Total Assets	$227.3M	$200.5M	$141.0M
YoY Change	-4.05%	-24.35%	-42.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.20M	$29.30M	$34.20M
YoY Change	-54.97%	-34.6%	23.91%
Accrued Expenses	$9.800M	$20.33M	$16.36M
YoY Change	-44.03%	-6.39%	-7.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.400M	$9.300M	$19.10M
YoY Change	-11.32%	-26.77%	44.7%
Total Short-Term Liabilities	$36.40M	$48.96M	$55.61M
YoY Change	-41.48%	-38.26%	-22.15%
LONG-TERM LIABILITIES
Long-Term Debt	$74.30M	$73.60M	$60.40M
YoY Change	1.09%	0.27%	22.52%
Other Long-Term Liabilities	$26.70M	$2.276M	$5.211M
YoY Change	434.0%	-52.17%	9.96%
Total Long-Term Liabilities	$101.0M	$2.276M	$5.211M
YoY Change	28.66%	-52.17%	9.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.40M	$48.96M	$55.61M
Total Long-Term Liabilities	$101.0M	$2.276M	$5.211M
Total Liabilities	$195.4M	$149.8M	$121.3M
YoY Change	1.3%	-4.89%	-3.35%
SHAREHOLDERS EQUITY
Retained Earnings		-$394.9M	-$396.3M
YoY Change		18.53%	26.96%
Common Stock		$63.00K	$58.00K
YoY Change		21.15%	13.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.90M	$20.82M	$1.852M
YoY Change
Total Liabilities & Shareholders Equity	$227.3M	$200.5M	$141.0M
YoY Change	-4.04%	-24.35%	-42.67%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q4
OPERATING ACTIVITIES
Net Income	-$13.10M	$1.392M	-$24.88M
YoY Change	-39.39%	-106.62%	138.93%
Depreciation, Depletion And Amortization	$500.0K	$481.0K	$740.0K
YoY Change	13.64%	145.41%	-161.67%
Cash From Operating Activities	-$28.32M	-$25.33M	-$22.16M
YoY Change	17.56%	-9.05%	6.18%
INVESTING ACTIVITIES
Capital Expenditures	-$660.0K	$300.0K	-$1.540M
YoY Change	-82.81%	-60.78%	-48.84%
Acquisitions
YoY Change
Other Investing Activities	$40.00K	$24.45M	$15.06M
YoY Change	-97.59%	-2363.89%	71.33%
Cash From Investing Activities	-$610.0K	$24.15M	$13.52M
YoY Change	-72.15%	-1412.39%	133.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$13.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	61.90M	52.11M	-1.690M
YoY Change	2175.74%	31.42%	-108.18%
NET CHANGE
Cash From Operating Activities	-28.32M	-25.33M	-22.16M
Cash From Investing Activities	-610.0K	24.15M	13.52M
Cash From Financing Activities	61.90M	52.11M	-1.690M
Net Change In Cash	32.97M	50.94M	-10.33M
YoY Change	-239.94%	410.84%	-285.46%
FREE CASH FLOW
Cash From Operating Activities	-$28.32M	-$25.33M	-$22.16M
Capital Expenditures	-$660.0K	$300.0K	-$1.540M
Free Cash Flow	-$27.66M	-$25.63M	-$20.62M
YoY Change	36.59%	-10.43%	15.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11833000
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116444000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65508000
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8022000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5498000
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	5044000
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	17604000
CY2019Q1	us-gaap	Inventory Net InventoryNet	629000
CY2018Q4	us-gaap	Inventory Net InventoryNet	678000
CY2019Q1	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	2129000
CY2018Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	2095000
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4281000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6735000
CY2019Q1	us-gaap	Assets Current AssetsCurrent	136549000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	111207000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12019000
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1884000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13478000
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	16074000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	16074000
CY2019Q1	us-gaap	Long Term Investments LongTermInvestments	11056000
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1183000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1417000
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1225000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	276000
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37073000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34067000
CY2019Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	16000
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	149000
CY2019Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1013000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1232000
CY2019Q1	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	97000
CY2018Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	97000
CY2019Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9277000
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9164000
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9914000
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	991000
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48957000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55614000
CY2019Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	73607000
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	60425000
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2276000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5211000
CY2019Q1	us-gaap	Liabilities Liabilities	149829000
CY2018Q4	us-gaap	Liabilities Liabilities	121250000
CY2019Q1	fbio	Sales Revenue Product Services Net SalesRevenueProductServicesNet	6125000
CY2018Q1	fbio	Sales Revenue Product Services Net SalesRevenueProductServicesNet	5509000
CY2019Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	352000
CY2018Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	394000
CY2019Q1	us-gaap	Revenues Revenues	6477000
CY2018Q1	us-gaap	Revenues Revenues	5903000
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1472000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23273000
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24958000
CY2019Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	450000
CY2018Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	97000
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13548000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	39085000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	40075000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32608000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-34172000
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	438000
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	278000
CY2019Q1	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	2469000
CY2018Q1	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	2403000
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-23000
CY2018Q1	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	250000
CY2018Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-118000
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16353000
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1970000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16255000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-36142000
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-16255000
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-38218000
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17647000
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17200000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1392000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-21018000
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-16255000
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-38218000
CY2019Q1	us-gaap	Depreciation Depreciation	481000
CY2018Q1	us-gaap	Depreciation Depreciation	196000
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	622000
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	661000
CY2019Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	234000
CY2018Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	133000
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3309000
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4795000
CY2019Q1	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	484000
CY2018Q1	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	489000
CY2018Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-118000
CY2018Q1	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-23000
CY2018Q1	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	250000
CY2019Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	450000
CY2018Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	97000
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2524000
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	556000
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-49000
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51000
CY2019Q1	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	34000
CY2018Q1	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	326000
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2483000
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1466000
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	949000
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	343000
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3664000
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6195000
CY2019Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-133000
CY2018Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-98000
CY2019Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-21000
CY2018Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	17000
CY2018Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-12000
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	888000
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	19000
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25325000
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27844000
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14878000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14583000
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3045000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2564000
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11833000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12019000
CY2019Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	450000
CY2018Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	97000
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	89492000
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	84406000
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6608000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4903000
CY2019Q1	us-gaap	Notes Payable NotesPayable	82884000
CY2018Q4	us-gaap	Notes Payable NotesPayable	79503000
CY2019Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1847000
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1742000
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	622000
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	661000
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1262000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1434000
CY2019Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5592000
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5843000
CY2019Q1	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	16000
CY2018Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	0
CY2019Q1	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	300000
CY2018Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	300000
CY2019Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1233000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1108000
CY2019Q1	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	993000
CY2018Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	838000
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4546000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1327000
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20327000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16360000
CY2019Q1	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	2276000
CY2018Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5211000
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2276000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5211000
CY2019Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	47539000
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17647000
CY2019Q1	us-gaap	Minority Interest MinorityInterest	29892000
CY2018	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	75680000
CY2018Q4	us-gaap	Minority Interest MinorityInterest	17891000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17688787
CY2019Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3309000
CY2018Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4795000
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6125000
CY2019Q1	us-gaap	Revenues Revenues	6477000
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	13089000
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	18384000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.34
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.85
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.05
CY2018Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-2076000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16255000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-36142000
CY2019Q1	fbio	Gain Or Loss From Deconsolidation Of Caelum GainOrLossFromDeconsolidationOfCaelum	-18384000
CY2018Q1	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsCurrent	-3383000
CY2018Q1	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Noncurrent IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	427000
CY2018Q1	fbio	Increase Decrease Disposal Group Including Discontinued Operation Liabilities Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationLiabilitiesCurrent	-4040000
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25325000
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25463000
CY2018Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2381000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	49522000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Commissions Compensation And Fees DisposalGroupIncludingDiscontinuedOperationCommissionsCompensationAndFees	43561000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Clearing Fees DisposalGroupIncludingDiscontinuedOperationClearingFees	743000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Communications DisposalGroupIncludingDiscontinuedOperationCommunications	760000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Occupancy DisposalGroupIncludingDiscontinuedOperationOccupancy	955000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Licenses And Registration DisposalGroupIncludingDiscontinuedOperationLicensesAndRegistration	637000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Professional Fees DisposalGroupIncludingDiscontinuedOperationProfessionalFees	1393000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	2000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	859000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	1781000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Change In Fair Value Of Derivative Liabilities DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfDerivativeLiabilities	-1088000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Interest Expense And Financing Fees DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndFinancingFees	-320000
CY2018Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	13089000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Effect Of Elimination Entry DisposalGroupIncludingDiscontinuedOperationEffectOfEliminationEntry	-305000
CY2018Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2381000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Proceeds From Sale Of Nhld Investments DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments	13089000
CY2019Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	13089000
CY2019Q1	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	4855000
CY2018Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	3805000
CY2019Q1	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	0
CY2018Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	200000
CY2019Q1	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	826000
CY2018Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	826000
CY2019Q1	fbio	Accrued Research And Development Expense Clinical Supplies AccruedResearchAndDevelopmentExpenseClinicalSupplies	215000
CY2018Q4	fbio	Accrued Research And Development Expense Clinical Supplies AccruedResearchAndDevelopmentExpenseClinicalSupplies	160000
CY2019Q1	fbio	Accrued Research And Development Expenselicense Maintenance Fees AccruedResearchAndDevelopmentExpenselicenseMaintenanceFees	489000
CY2018Q4	fbio	Accrued Research And Development Expenselicense Maintenance Fees AccruedResearchAndDevelopmentExpenselicenseMaintenanceFees	519000
CY2018Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	75000
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	300000
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	765000
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	25000000
CY2019Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	12560000
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	24000000
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	223000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	336000
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	6385000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	4567000
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2019Q1	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000
CY2019Q1	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2018Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63126521
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57845447
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63126521
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57845447
CY2019Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	475225
CY2018Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	744332
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	3309000
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0
CY2019Q1	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	6142000
CY2019Q1	fbio	Common Shares Issuable For Subordinated Note Financial Interest Expenses CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses	484000
CY2019Q1	fbio	Common Shares Issued For Subordinated Note Financial Interest Expenses CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses	0
CY2019Q1	fbio	Common Shares Issued For Opus Interest Expenses In Value CommonSharesIssuedForOpusInterestExpensesInValue	281000
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17647000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1392000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	4795000
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0
CY2018Q1	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	318000
CY2018Q1	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	-6000
CY2018Q1	fbio	Common Shares Issuable For Subordinated Note Financial Interest Expenses CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses	489000
CY2018Q1	fbio	Common Shares Issued For Subordinated Note Financial Interest Expenses CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses	0
CY2018Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	586000
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17200000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-21018000
CY2019Q1	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11059000
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1840000
CY2019Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	13089000
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24148000
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1840000
CY2019Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	586000
CY2018Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	586000
CY2019Q1	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	6251000
CY2018Q1	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	229000
CY2019Q1	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	109000
CY2018Q1	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	6000
CY2019Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	34999000
CY2018Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23011000
CY2019Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3500000
CY2018Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2167000
CY2019Q1	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	366000
CY2019Q1	fbio	Payment Of Cost Related To Subsidiaries At The Market Offering PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering	11000
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	96000
CY2018Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	255000
CY2018Q1	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	21707000
CY2019Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	67000
CY2018Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1814000
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	15000000
CY2019Q1	fbio	Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes	230000
CY2018Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1858000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50936000
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9971000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81582000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110958000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132518000
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120929000
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	1100000
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	394000
CY2018Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	853000
CY2019Q1	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	2000
CY2018Q1	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	1000
CY2019Q1	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	1202000
CY2019Q1	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	164000
CY2019Q1	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	495000
CY2018Q1	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	500000
CY2019Q1	fbio	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable	191000
CY2018Q1	fbio	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable	2321000
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y8M4D
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1085501
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.75
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y11M4D
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2019Q1	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1085501
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.75
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	155322000
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y8M4D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1085501
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.75
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	155322000
CY2019Q1	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-351000
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11056000
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	10905000
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22618000
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1481000
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24989000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48506994
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42518403
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63811136
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42518403
CY2019Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	586000
CY2019Q1	fbio	Adjustments To Additional Paid In Capital Partner Sale Of Stock Net AdjustmentsToAdditionalPaidInCapitalPartnerSaleOfStockNet	31499000
CY2019Q1	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	355000
CY2019Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	4849000
CY2019Q1	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	0
CY2019Q1	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0
CY2018Q1	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	22000
CY2018Q1	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	20844000
CY2018Q1	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	96000
CY2018Q1	fbio	Adjustments To Additional Paid In Capital Disposal Of National AdjustmentsToAdditionalPaidInCapitalDisposalOfNational	-710000
CY2018Q1	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0
CY2019Q1	fbio	Amortization Of Operating Lease Right Of Use Asset AmortizationOfOperatingLeaseRightOfUseAsset	381000
CY2019Q1	fbio	Proceeds From Deconsolidation Of Caelum ProceedsFromDeconsolidationOfCaelum	-1201000
CY2018Q1	fbio	Receivable From Atm Issuances ReceivableFromAtmIssuances	89000
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	767000
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22618000
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Interest Income DisposalGroupIncludingDiscontinuedOperationInterestIncome	6000
CY2018Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-2076000
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	1201000
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	6000
CY2019Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1207000
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	2246000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Interest Payable DisposalGroupIncludingDiscontinuedOperationInterestPayable	198000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Note Payable Related Party DisposalGroupIncludingDiscontinuedOperationNotePayableRelatedParty	929000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Note Payable DisposalGroupIncludingDiscontinuedOperationNotePayable	9914000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Warrant Liability DisposalGroupIncludingDiscontinuedOperationWarrantLiability	991000
CY2019Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	14384000
CY2019Q1	fbio	Net Liabilities Impacted By Deconsolidation NetLiabilitiesImpactedByDeconsolidation	13177000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Interest Payable Related Party DisposalGroupIncludingDiscontinuedOperationInterestPayableRelatedParty	106000
CY2019Q1	fbio	Fair Value Of Caelum FairValueOfCaelum	11056000
CY2019Q1	fbio	Net Liabilities Impacted By Deconsolidation NetLiabilitiesImpactedByDeconsolidation	13177000
CY2019Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	4849000
CY2019Q1	fbio	Write Off Of Msa Fee Due Fortress WriteOffOfMsaFeeDueFortress	-1000000
CY2019Q1	fbio	Gain From Deconsolidation Of Caelum GainFromDeconsolidationOfCaelum	18384000
CY2019Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	11056000
CY2019Q1	fbio	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	378835
CY2018Q1	fbio	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	0
CY2019Q1	fbio	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	60000
CY2018Q1	fbio	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	0
CY2019Q1	fbio	Incremental Common Shares Attributable To Unvested Restricted Stock IncrementalCommonSharesAttributableToUnvestedRestrictedStock	12622076
CY2018Q1	fbio	Incremental Common Shares Attributable To Unvested Restricted Stock IncrementalCommonSharesAttributableToUnvestedRestrictedStock	0
CY2019Q1	fbio	Incremental Common Shares Attributable To Unvested Restricted Stock Units IncrementalCommonSharesAttributableToUnvestedRestrictedStockUnits	1243231
CY2018Q1	fbio	Incremental Common Shares Attributable To Unvested Restricted Stock Units IncrementalCommonSharesAttributableToUnvestedRestrictedStockUnits	0
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63811136
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42518403
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2019Q1	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	At its option, upon ten business days’ prior written notice to Horizon, Mustang may prepay all or any portion greater than or equal to $500,000 of each of the outstanding advances by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest, subject to a prepayment charge of 4.0% of the then outstanding principal balance of each advance if such advance is prepaid on or before the Loan Amortization Date (as defined in the Loan Agreement), 3% if such advance is prepaid after the Loan Amortization Date applicable to such Loan, but on or prior to twelve months following the Loan Amortization Date, and 2% thereafter. In addition, a final payment equal to $0.3 million for each advance (i.e., $0.8 million in aggregate with respect to the initial $15.0 million) is due on the maturity date or other date of payment in full. Amounts outstanding during an event of default shall be payable on demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding.
CY2019Q1	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	9.0% plus one-month LIBOR Rate
CY2019Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.025
CY2019Q1	fbio	Percentage Of Warrants Included In Debt PercentageOfWarrantsIncludedInDebt	0.05
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	288184
CY2019Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.47
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1871000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3351000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3114000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3084000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3137000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	23463000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	38020000
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11550000
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	26470000
CY2014Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P15Y
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19743000
CY2014Q4	fbio	Lessee Operating Lease Annual Average Rental Expense LesseeOperatingLeaseAnnualAverageRentalExpense	2700000
CY2014Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	40700000
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50709000
CY2015Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2015Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	6100
CY2015Q4	fbio	Lessee Operating Lease Annual Average Rental Expense LesseeOperatingLeaseAnnualAverageRentalExpense	200000
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	107546000
CY2019Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	16000000
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1392000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-21018000
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48506994
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42518403
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	1000000
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	120502000
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
CY2019Q1	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	888000
CY2019Q1	fbio	Common Stock Issuable For Opus Interest Expense CommonStockIssuableForOpusInterestExpense	281000
CY2018Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1298000
CY2019Q1	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	888000
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-57789000
CY2018Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-2076000
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Trading Symbol TradingSymbol	FBIO
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65230630
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	1000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	63000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	58000
CY2019Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	765000
CY2018Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	659000
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	414870000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397408000
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394882000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396274000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	20817000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1852000
CY2019Q1	us-gaap	Minority Interest MinorityInterest	29892000
CY2018Q4	us-gaap	Minority Interest MinorityInterest	17891000
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50709000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19743000
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	200538000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140993000
CY2019Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	0
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2019Q1	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0
CY2019Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Underwriting Costs DisposalGroupIncludingDiscontinuedOperationUnderwritingCosts	145000
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5509000
CY2018Q1	us-gaap	Revenues Revenues	5903000
CY2019Q1	us-gaap	Assets Assets	200538000
CY2018Q4	us-gaap	Assets Assets	140993000
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52113000
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39655000
CY2019Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2018Q4	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.333
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	180000000
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2076000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	50836000
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-1314000
CY2018Q1	fbio	Disposal Group Including Discontinued Operation Total Other Expenses Income DisposalGroupIncludingDiscontinuedOperationTotalOtherExpensesIncome	-762000
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue
CY2019Q1	fbio	Annual Management Services Agreement Fee Income Expense Written Off AnnualManagementServicesAgreementFeeIncomeExpenseWrittenOff	1000000
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2469000
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2403000
CY2019Q1	fbio	Disposal Group Including Discontinued Operation Effect Of Elimination Entry DisposalGroupIncludingDiscontinuedOperationEffectOfEliminationEntry
CY2019Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	796000
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	477000
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	26000
CY2019Q1	us-gaap	Lease Cost LeaseCost	345000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3070000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3289000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3084000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3084000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3137000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	23466000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	39130000
CY2019Q1	fbio	Contingent Earn Out Payments Measurement Second Model ContingentEarnOutPaymentsMeasurementSecondModel	at any time beginning on January 1, 2029 that IV Tramadol has generated at least $1.5 billion in aggregate Net Sales, then with respect to each calendar year in which IV Tramadol generates $100 million or more in Net Sales, each Holder shall be entitled to receive their pro rata share of an amount equal to 20% of the Gross Profit generated by IV Tramadol
CY2019Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	900000
CY2019Q1	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	The events of default under the Loan Agreement include, among other things, without limitation, and subject to customary grace periods, (1) Mustang’s failure to make any payments of principal or interest under the Loan Agreement, promissory notes or other loan documents, (2) Mustang’s breach or default in the performance of any covenant under the Loan Agreement, (3) the occurrence of a material adverse change, (4) Mustang making a false or misleading representation or warranty in any material respect, (5) Mustang’s insolvency or bankruptcy, (6) certain attachments or judgments on the Mustang’s assets, (7) the occurrence of any material default under certain agreements or obligations of Mustang involving indebtedness in excess of $0.3 million or (8) failing to maintain minimum monthly cash balances which range from approximately $8.0 to $13.0 million over the term of the loan. If an event of default occurs, Horizon is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	13089000
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	13089000

Files In Submission

Name	View Source	Status
0001144204-19-025261-index-headers.html	Edgar Link	pending
0001144204-19-025261-index.html	Edgar Link	pending
0001144204-19-025261.txt	Edgar Link	pending
0001144204-19-025261-xbrl.zip	Edgar Link	pending
fbio-20190331.xml	Edgar Link	completed
fbio-20190331.xsd	Edgar Link	pending
fbio-20190331_cal.xml	Edgar Link	unprocessable
fbio-20190331_def.xml	Edgar Link	unprocessable
fbio-20190331_lab.xml	Edgar Link	unprocessable
fbio-20190331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv520144_10q.htm	Edgar Link	pending
tv520144_ex10-1.htm	Edgar Link	pending
tv520144_ex31-1.htm	Edgar Link	pending
tv520144_ex31-2.htm	Edgar Link	pending
tv520144_ex32-1.htm	Edgar Link	pending
tv520144_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2019 Q2 Form 10-Q Financial Statement

#000114420419025261 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2019 Q2 Form 10-Q Financial Statement

#000114420419025261 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio